<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02296580</url>
  </required_header>
  <id_info>
    <org_study_id>NAT-101</org_study_id>
    <nct_id>NCT02296580</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nativis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nativis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility study will assess the effects of the Nativis Voyager therapy in patients
      with first or second recurrence of GBM who have either failed standard of care or are
      intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus
      lomustine. Safety and clinical utility will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This feasibility study will assess the effects of the Nativis Voyager therapy in patients
      with first or second recurrence of GBM who have either failed standard of care or are
      intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus
      lomustine (CCNU). Safety and clinical utility will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of any adverse events associated with the investigational therapy.</measure>
    <time_frame>Through one month following investigational treatment</time_frame>
    <description>Safety Assessment as assessed by adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Utility: PFS</measure>
    <time_frame>Six months</time_frame>
    <description>Progression Free Survival as assessed by RANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Utility: OS</measure>
    <time_frame>18 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Nativis Voyager RFE Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with Nativis Voyager therapy until tumor progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nativis Voyager RFE Therapy</intervention_name>
    <description>Nativis Voyager Radiofrequency Energy Therapy</description>
    <arm_group_label>Nativis Voyager RFE Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has histologically confirmed diagnosis of GBM.

          -  Subject has failed or intolerant to radiotherapy.

          -  Subjects has failed or intolerant to temozolomide therapy.

          -  Subject has progressive disease with at least one measureable lesion on MRI.

          -  Subject is at least 18 years of age.

          -  Subject has a KPS ≥ 60.

          -  Subject has adequate organ and marrow function.

        Exclusion Criteria:

          -  Subject has received bevacizumab (Avastin).

          -  Subjecting has any condition, including compromised pulmonary function, that would
             preclude the use of lomustine.

          -  Subject is currently being treated with other investigational agents.

          -  Subject has received other investigational therapy within the last 28 days.

          -  Subject has received surgery within the last four weeks.

          -  Subject is within 12 weeks of completion of radiation.

          -  Subject has an active implantable or other electromagnetic device.

          -  Subject has a metal implant, including a programmable shunt, in the head or neck that
             is incompatible with MRI.

          -  Subject is known to be HIV positive.

          -  Subject is pregnant, nursing or intends to become pregnant during the course of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Morgan Murray, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nativis, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Morgan Murray, PhD</last_name>
    <phone>206-708-2288</phone>
    <phone_ext>109</phone_ext>
    <email>dmorganmurray@nativis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru Pillay, RN BSN</last_name>
      <phone>205-934-1842</phone>
      <email>tpillay@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Burt Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Pazzi, RN, MSN</last_name>
      <phone>520-320-2147</phone>
      <email>mpazzi@neurotucson.com</email>
    </contact>
    <contact_backup>
      <phone>520.795.7750</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Badruddoja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>cCARE - California Cancer Associates for Research &amp; Excellence</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Kimball</last_name>
      <phone>760-452-3909</phone>
      <email>bkimball@ccare.com</email>
    </contact>
    <investigator>
      <last_name>Edward McClay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute @ Providecne St. Johns Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Moses</last_name>
      <phone>310-582-7097</phone>
      <email>mosesa@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Garni Barkhoudarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern CT, P.C.</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tori Pascoe, CRC</last_name>
      <phone>203-333-1151</phone>
      <phone_ext>4</phone_ext>
      <email>tpascoe@anscneuro.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Blondin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Zuniga, MD</last_name>
      <phone>561-955-4800</phone>
      <email>pzuniga@brrh.com</email>
    </contact>
    <investigator>
      <last_name>Sajeel Chowdhary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (KUMC)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sasha Moores</last_name>
      <phone>913-588-5520</phone>
      <email>smoores@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Salacz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Collaborative</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Herndon, RN</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77713</phone_ext>
      <email>hherndon@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Brian D Vaillant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dedra Preece, BS, CCRP</last_name>
      <phone>254-724-5939</phone>
      <email>dedra.preece@bswhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Gates Anderson</last_name>
      <phone>254.724.5889</phone>
      <email>Gates.Anderson@bswhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ekokobe Fonkem, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Hospital &amp; Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Priest</last_name>
      <phone>03 9231 3551</phone>
      <email>emma.priest@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Michael Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

